Revisional laparoscopic antireflux surgery after unsuccessful endoscopic fundoplication

Surg Endosc. 2013 Jun;27(6):2231-6. doi: 10.1007/s00464-012-2685-6. Epub 2013 Jan 5.

Abstract

Background: Transoral incisionless fundoplication (TIF), a novel endoscopic procedure for treating gastroesophageal reflux disease (GERD), currently is under evaluation. In case of treatment failure, subsequent revisional laparoscopic antireflux surgery (rLARS) may be required. This study aimed to evaluate the feasibility, safety, and outcomes of revisional antireflux surgery after previous endoscopic fundoplication.

Methods: Chronic GERD patients who underwent rLARS after a previous TIF procedure were included in the study. Pre- and postoperative assessment included GERD-related quality-of-life scores, proton pump inhibitor (PPI) usage, 24-h pH-metry, upper gastrointestinal endoscopy, and registration of adverse events.

Results: Revisional laparoscopic Nissen fundoplication was feasible for all 15 patients included in the study without conversions to open surgery. Acid exposure of the distal esophagus improved significantly after rLARS, and esophagitis, PPI usage, and hiatal hernia decreased. Quality of life did not improve significantly after rLARS, and 33 % of the patients experienced dysphagia.

Conclusion: Revisional laparoscopic Nissen fundoplication was feasible and safe after unsuccessful endoscopic fundoplication, resulting in objective reflux control at the cost of a relatively high rate of dysphagia.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Deglutition Disorders / etiology
  • Endoscopy, Gastrointestinal / adverse effects
  • Endoscopy, Gastrointestinal / methods*
  • Feasibility Studies
  • Fundoplication / methods*
  • Gastroesophageal Reflux / drug therapy
  • Gastroesophageal Reflux / surgery*
  • Humans
  • Laparoscopy / adverse effects
  • Laparoscopy / methods*
  • Middle Aged
  • Patient Satisfaction
  • Proton Pump Inhibitors / therapeutic use
  • Quality of Life
  • Reoperation

Substances

  • Proton Pump Inhibitors